FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2215668323> ?p ?o ?g. }

• W2215668323 endingPage "10006" @default.
• W2215668323 startingPage "10006" @default.
• W2215668323 abstract "10006 Background: Dasatinib is an oral tyrosine kinase inhibitor of KIT, PDGFR, ABL and SRC with a distinct binding affinity for KIT and PDGFR. We performed a phase II trial to assess antitumor activity of dasatinib in patients (pts) with advanced GIST who were refractory to imatinib (IM) and sunitinib malate (SM). Methods: Pts received dasatinib 70mg PO BID. Computer tomographic response rates (ORR) was evaluated every 8 wks by Choi criteria. The primary endpoint was a target progression-free survival at 6 months (PFS-6) of >30% with <10% deemed inactive by a Bayesian approach. Objective response rate (ORR) per Choi criteria was also determined. Results: From 8/2008 to 7/2010, 50 pts were accrued (47 evaluable for response). Median age was 60(range, 20-78), 62% were male, and median ECOG PS=1. The most common site of primary disease was stomach (59%) and metastasis was liver (56%). Primary median tumor size at diagnosis was 8.7 cm(range 3.7-26) and mitotic rate was >5/50 hpf in 74% of patients. Tumor morphology was spindled (63%), epithelioid (18%) or mixed (18%). The median number of prior therapies was 2[range 1-6, IM (100%), SM (80%)]. Genotype was available for 15 pts: 6(40%) KIT exon 11, 6(40%) WT, 2(13%) KIT exon 9, and 1(7%) had PDGFR D842V. The median number of cycles was 2 (range, 1-24). The PR rate was 32% (15/47) by Choi criteria. 21% patients (10/47) were progression-free >6 months. Median PFS and OS were 2.0 months and 19 months. Median PFS for patients with WT GIST was 8.4 months (range 1.2-27). Toxicity was assessed in all pts: 14 grade 3 events (28%; constitutional, GI, respiratory, and myelosuppression) and 1 grade 4 event (2%, pain). There were no deaths related to dasatinib. Conclusions: Dasatinib has significant activity by ORR in IM and SM-refractory GIST but did not meet the predefined 6 month PFS rate of 30%. Mutational and molecular correlates are forthcoming." @default.
• W2215668323 created "2016-06-24" @default.
• W2215668323 creator A5004418792 @default.
• W2215668323 creator A5016367638 @default.
• W2215668323 creator A5020992966 @default.
• W2215668323 creator A5036766883 @default.
• W2215668323 creator A5042786571 @default.
• W2215668323 creator A5056161574 @default.
• W2215668323 creator A5059734562 @default.
• W2215668323 creator A5071532449 @default.
• W2215668323 creator A5075212929 @default.
• W2215668323 creator A5077232908 @default.
• W2215668323 creator A5085336500 @default.
• W2215668323 creator A5087253387 @default.
• W2215668323 creator A5089966140 @default.
• W2215668323 date "2011-05-20" @default.
• W2215668323 modified "2023-09-30" @default.
• W2215668323 title "A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)." @default.
• W2215668323 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.10006" @default.
• W2215668323 hasPublicationYear "2011" @default.
• W2215668323 type Work @default.
• W2215668323 sameAs 2215668323 @default.
• W2215668323 citedByCount "47" @default.
• W2215668323 countsByYear W22156683232012 @default.
• W2215668323 countsByYear W22156683232013 @default.
• W2215668323 countsByYear W22156683232014 @default.
• W2215668323 countsByYear W22156683232015 @default.
• W2215668323 countsByYear W22156683232016 @default.
• W2215668323 countsByYear W22156683232017 @default.
• W2215668323 countsByYear W22156683232018 @default.
• W2215668323 countsByYear W22156683232019 @default.
• W2215668323 countsByYear W22156683232020 @default.
• W2215668323 countsByYear W22156683232021 @default.
• W2215668323 countsByYear W22156683232022 @default.
• W2215668323 countsByYear W22156683232023 @default.
• W2215668323 crossrefType "journal-article" @default.
• W2215668323 hasAuthorship W2215668323A5004418792 @default.
• W2215668323 hasAuthorship W2215668323A5016367638 @default.
• W2215668323 hasAuthorship W2215668323A5020992966 @default.
• W2215668323 hasAuthorship W2215668323A5036766883 @default.
• W2215668323 hasAuthorship W2215668323A5042786571 @default.
• W2215668323 hasAuthorship W2215668323A5056161574 @default.
• W2215668323 hasAuthorship W2215668323A5059734562 @default.
• W2215668323 hasAuthorship W2215668323A5071532449 @default.
• W2215668323 hasAuthorship W2215668323A5075212929 @default.
• W2215668323 hasAuthorship W2215668323A5077232908 @default.
• W2215668323 hasAuthorship W2215668323A5085336500 @default.
• W2215668323 hasAuthorship W2215668323A5087253387 @default.
• W2215668323 hasAuthorship W2215668323A5089966140 @default.
• W2215668323 hasConcept C121332964 @default.
• W2215668323 hasConcept C121608353 @default.
• W2215668323 hasConcept C126322002 @default.
• W2215668323 hasConcept C142424586 @default.
• W2215668323 hasConcept C143998085 @default.
• W2215668323 hasConcept C16930146 @default.
• W2215668323 hasConcept C203092338 @default.
• W2215668323 hasConcept C2775922572 @default.
• W2215668323 hasConcept C2776694085 @default.
• W2215668323 hasConcept C2777007597 @default.
• W2215668323 hasConcept C2777583451 @default.
• W2215668323 hasConcept C2778729363 @default.
• W2215668323 hasConcept C2778820342 @default.
• W2215668323 hasConcept C2779490328 @default.
• W2215668323 hasConcept C2779536868 @default.
• W2215668323 hasConcept C2780739268 @default.
• W2215668323 hasConcept C2908861226 @default.
• W2215668323 hasConcept C31760486 @default.
• W2215668323 hasConcept C535046627 @default.
• W2215668323 hasConcept C71924100 @default.
• W2215668323 hasConcept C87355193 @default.
• W2215668323 hasConcept C90924648 @default.
• W2215668323 hasConceptScore W2215668323C121332964 @default.
• W2215668323 hasConceptScore W2215668323C121608353 @default.
• W2215668323 hasConceptScore W2215668323C126322002 @default.
• W2215668323 hasConceptScore W2215668323C142424586 @default.
• W2215668323 hasConceptScore W2215668323C143998085 @default.
• W2215668323 hasConceptScore W2215668323C16930146 @default.
• W2215668323 hasConceptScore W2215668323C203092338 @default.
• W2215668323 hasConceptScore W2215668323C2775922572 @default.
• W2215668323 hasConceptScore W2215668323C2776694085 @default.
• W2215668323 hasConceptScore W2215668323C2777007597 @default.
• W2215668323 hasConceptScore W2215668323C2777583451 @default.
• W2215668323 hasConceptScore W2215668323C2778729363 @default.
• W2215668323 hasConceptScore W2215668323C2778820342 @default.
• W2215668323 hasConceptScore W2215668323C2779490328 @default.
• W2215668323 hasConceptScore W2215668323C2779536868 @default.
• W2215668323 hasConceptScore W2215668323C2780739268 @default.
• W2215668323 hasConceptScore W2215668323C2908861226 @default.
• W2215668323 hasConceptScore W2215668323C31760486 @default.
• W2215668323 hasConceptScore W2215668323C535046627 @default.
• W2215668323 hasConceptScore W2215668323C71924100 @default.
• W2215668323 hasConceptScore W2215668323C87355193 @default.
• W2215668323 hasConceptScore W2215668323C90924648 @default.
• W2215668323 hasIssue "15_suppl" @default.
• W2215668323 hasLocation W22156683231 @default.
• W2215668323 hasOpenAccess W2215668323 @default.
• W2215668323 hasPrimaryLocation W22156683231 @default.
• W2215668323 hasRelatedWork W1559702962 @default.

• next